Navigation Links
Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
Date:3/6/2009

PRINCETON, N.J., March 6 /PRNewswire-FirstCall/ -- Orchid Cellmark Inc. (Nasdaq: ORCH), a leading worldwide provider of identity DNA testing services, will release its fourth quarter and year-end 2008 financial results on Monday, March 16, 2009 at approximately 7:00 a.m. EDT, and is hosting a conference call and webcast to discuss the results at 10:00 a.m. EDT on the same day. Management will discuss financial results for the 2008 fourth quarter and year-end results as well as operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

    Conference Call Details

    Date and Time:   Monday, March 16, 2009 at 10:00 a.m. EDT

    Dial-In:         US/Canada:      (877) 266-0703
                     Int'l/Local:    (706) 643-7682
                     Conference ID:  88572934

Webcast: Live webcast and replay available via the Investor Relations section of the company's website at www.orchidcellmark.com. The webcast will be available for 90 days.

About Orchid Cellmark

Orchid Cellmark (Nasdaq: ORCH) is a leading international provider of DNA testing services primarily for forensic and family relationship applications. Orchid Cellmark is one of the largest providers of forensic DNA testing services and its DNA results are used by the criminal justice system to assist with the identification of perpetrators, the exclusion of suspects and the exoneration of wrongfully convicted individuals. The company provides DNA family relationship testing to numerous child services organizations and individuals seeking to verify parentage. Orchid Cellmark also serves immigration and security authorities for DNA testing of individuals. In the agriculture field, the company provides DNA testing services for selective trait breeding. Orchid Cellmark's strong market positions in these areas reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise, and the company's reputation for exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at www.orchidcellmark.com.

All statements in this press release that are not historical are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, risks and uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, and Orchid Cellmark's ability to successfully offer its services directly to U.K. police forces. These risks and other additional factors affecting these forward-looking statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2007, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Securities and Exchange Commission from time to time. Orchid Cellmark expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Orchid Cellmark's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based, except as may be required by law.


'/>"/>
SOURCE Orchid Cellmark Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Orchid Cellmark Reports Third Quarter 2008 Financial Results
2. Orchid Cellmark Reports Second Quarter 2008 Financial Results
3. Orchid Cellmark To Announce Second Quarter 2008 Financial Results on July 31, 2008
4. Orchid Cellmark Reports First Quarter 2008 Financial Results
5. Orchid Cellmark to Open a New Forensic Facility in the United Kingdom to Meet Increasing Demand for Its Services
6. Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
7. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
8. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
9. Orchid Cellmark Reports Third Quarter 2007 Financial Results
10. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
11. Gaiam to Announce Fourth Quarter 2008 and Year End Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... (PRWEB) , ... January 18, 2017 , ... The CHP ... driving during a rain storm by slowing down and increasing the space between themselves ... 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, rain or ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... text designs that will simplify the editing process for all media productions," said ... is a package of 30 simplistically styled self-animating paragraphs designed for multi-lined text ...
(Date:1/18/2017)... ... January 18, 2017 , ... A recent video posting ... global discussion about the benefits of fidgeting to relieve stress and anxiety. No ... Their Think Ink Pen had just completed a successful Kickstarter campaign raising $67,000 ...
(Date:1/18/2017)... USA; SAN JOSE, Calif, USA; and SHANGHAI, China – , ... ... (PRWEB) January 18, 2017 -- Global public health organization NSF ... arsenic V (pentavalent arsenic) to NSF/ANSI 53: Drinking Water Treatment ... water treatment units. This certification verifies that MicroCeramics’ NanoNose Pitcher ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Portee Insurance Agency, a ... business owners in central Maryland and the DC region, is inaugurating a charity event ... people nationally every year, making it the #1 killer in America. However, heart disease ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
(Date:1/19/2017)... LONDON , Jan. 18, 2017 ... 2022 Summary GlobalData,s new report, "South Korea ... data on the South Korea Insulin Delivery market. The ... (in units) and average prices (USD) within market segments ... Insulin Pump Accessories. The report also provides company ...
(Date:1/18/2017)... PUNE, India , January 18, 2017 ... titled, "Breast Imaging Technologies Market by Type: Global Opportunity Analysis ... technologies market size was valued at $2,544 million in 2015 ... at a CAGR of 8.4% from 2016 to 2022. ... together accounted for over three-fourths market share in 2015. ...
Breaking Medicine Technology: